Expertise in
9
conditions

Dr. Akgun Ince

Rheumatology
Mercy Labs South LLC
10010 Kennerly Rd, 
Saint Louis, MO 
Accepting New Patients
Expertise in
9
conditions
Mercy Labs South LLC
10010 Kennerly Rd, 
Saint Louis, MO 

Overview

Akgun Ince is a Rheumatologist practicing medicine in Saint Louis, Missouri.

Dr. Ince is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Rheumatoid Arthritis (RA), Psoriatic Arthritis, Rhizomelic Pseudopolyarthritis, and Polymyalgia Rheumatica.

He is actively involved in clinical research, co-authoring 4 peer reviewed articles and participating in 7 clinical trials. Dr. Ince is currently accepting new patients.

Specialties

Rheumatology

Licenses

Internal Medicine in MO

Hospital Affiliations

Mercy Hospital St Louis
Mercy Hospital South
Mercy Hospital Jefferson

Languages Spoken

English
Turkish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Celtic
  • HMO
  • INSURANCE PLAN
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Dean Health
  • EPO
  • HMO
  • POS
  • PPO
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Home State Health
  • EPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MetLife
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
SelectHealth
  • HMO
  • POS
TeamCare
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 21 Less Insurance Carriers -

Locations

Mercy Labs South LLC
10010 Kennerly Rd, Saint Louis, MO 63128

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: June 24, 2026
Intervention Type: Drug
Study Drugs: Baricitinib, TNF Inhibitor
Study Phase: Phase 4
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study Comparing GSK3196165 With Placebo and With Tofacitinib, in Combination With Methotrexate in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study Comparing GSK3196165 With Placebo and With Tofacitinib, in Combination With Methotrexate in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
Enrollment Status: Completed
Publish Date: March 27, 2024
Intervention Type: Biological, Drug
Study Drugs: GSK3196165, Tofacitinib, Methotrexate, Folic acid
Study Phase: Phase 3
A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
A Multi-centre Long-term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis
Enrollment Status: Terminated
Publish Date: February 07, 2024
Intervention Type: Drug, Biological
Study Drugs: Otilimab, csDMARD
Study Phase: Phase 3
A 24-week, Phase 3, Multicentre, Randomised, Double-blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Sarilumab, in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological DMARDs and/or Janus Kinase Inhibitors
A 24-week, Phase 3, Multicentre, Randomised, Double-blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Sarilumab, in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological DMARDs and/or Janus Kinase Inhibitors
Enrollment Status: Completed
Publish Date: July 17, 2023
Intervention Type: Drug, Biological
Study Drugs: GSK3196165, Sarilumab, csDMARDs
Study Phase: Phase 3
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: June 13, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis
A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: June 17, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients With Radiographic Axial Spondyloarthritis
A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients With Radiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: November 19, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 6 Less Clinical Trials

4 Total Publications

Assessing Rheumatoid Arthritis Disease Activity Measures in Ethnic Minority Patients in the United States: Real-World Data From the Ethnic Minority Rheumatoid Arthritis Consortium Registry.
Assessing Rheumatoid Arthritis Disease Activity Measures in Ethnic Minority Patients in the United States: Real-World Data From the Ethnic Minority Rheumatoid Arthritis Consortium Registry.
Journal: Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
Published: August 12, 2025
Similar Doctors
Expertise in
13
conditions
Dr. John J. Budd
Rheumatology
Expertise in
13
conditions
Dr. John J. Budd
Rheumatology
Referral may be required
Before you request

Clayton Medical Associates PC

520 S Elm Ave, 
Saint Louis, MO 
 (5.4 miles away)
314-645-4434
Languages Spoken:
English
See accepted insurances
Accepting New Patients

John Budd is a Rheumatologist practicing medicine in Saint Louis, Missouri. Dr. Budd is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Rheumatoid Arthritis (RA), Synovitis, Psoriatic Arthritis, and Psoriasis. Dr. Budd is currently accepting new patients.

Expertise in
17
conditions
Dr. Sona S. Kamat
Rheumatology
Expertise in
17
conditions
Dr. Sona S. Kamat
Rheumatology
Referral may be required
Before you request

Office

13100 Manchester Rd Ste 70, 
Saint Louis, MO 
 (7.9 miles away)
314-492-2323
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients

Sona Kamat is a Rheumatologist practicing medicine in Saint Louis, Missouri. Dr. Kamat is highly rated in 17 conditions, according to our data. Her clinical expertise encompasses Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Scleroma, and Psoriatic Arthritis. Dr. Kamat is currently accepting new patients.

Expertise in
20
conditions
Expertise in
20
conditions
Referral may be required
Before you request

Washington University School Of Medicine

4921 Parkview Pl, 
Saint Louis, MO 
 (11.1 miles away)
314-286-2635
Experience:
44+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Deborah Parks is a Rheumatologist practicing medicine in Saint Louis, Missouri. She has been practicing medicine for over 44 years. Dr. Parks is highly rated in 20 conditions, according to our data. Her clinical expertise encompasses Rheumatoid Arthritis (RA), Osteoporosis, Postmenopausal Osteoporosis, Psoriasis, and Tissue Biopsy. Dr. Parks is currently accepting new patients.

Frequently Asked Questions about Dr. Akgun Ince

Is Dr. Akgun Ince a top-rated expert for Rheumatoid Arthritis (RA)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Akgun Ince is classified as an Distinguished expert for Rheumatoid Arthritis (RA), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Akgun Ince specialize in?

While Dr. Akgun Ince is a Rheumatology, they have specific expertise in Rheumatoid Arthritis (RA), Psoriatic Arthritis, and Rhizomelic Pseudopolyarthritis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Rheumatology.

Does Dr. Akgun Ince participate in research or clinical trials?

Yes. Dr. Akgun Ince has published 4 articles and abstracts on conditions like Rheumatoid Arthritis (RA). You can view a list of Dr. Akgun Ince's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Akgun Ince accept my insurance?

Dr. Akgun Ince accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ince's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 11 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile